The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial.

Iino, S; Toyota, J; Kumada, H; Kiyosawa, K; Kakumu, S; Sata, M; Suzuki, H; Martins, E B

Iino, S; Toyota, J; Kumada, H; Kiyosawa, K; Kakumu, S; Sata, M; Suzuki, H; Martins, E B.

Affiliation

Iino S; Department of Gastroenterology, St Marianna University, School of Medicine, Kawasaki, Kanagawa, Japan.

J Viral Hepat ; 12(3): 300-6, 2005 May.

Article in En | MEDLINE | ID: mdl-15850471

Subject(s)

Adjuvants, Immunologic/administration & dosage; DNA, Viral/drug effects; Hepatitis B, Chronic/drug therapy; Hepatitis B, Chronic/pathology; Thymosin/analogs & derivatives; Thymosin/administration & dosage; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunohistochemistry; Japan; Liver Function Tests; Male; Maximum Tolerated Dose; Middle Aged; Probability; Risk Assessment; Severity of Illness Index; Thymalfasin; Time Factors; Treatment Outcome; Viral Load

Search on Google

XML

PubMed Links

Collection: 01-internacional Health context: 2_ODS3 Database: MEDLINE Main subject: Thymosin / DNA, Viral / Adjuvants, Immunologic / Hepatitis B, Chronic Type of study: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: J Viral Hepat Year: 2005 Document type: Article

Search on Google

XML

PubMed Links